Diabetes: Page 7

  • From left to right: A white, rectangular device that says "EO," a black device with a screen that says "EOWatch," and a smartphone.
    Image attribution tooltip
    Courtesy of EOFlow
    Image attribution tooltip

    Medtronic scraps plans to buy insulin patch-pump maker EOFlow

    Medtronic cited “multiple breaches” of the companies’ agreements. EOFlow has been embroiled in patent lawsuits with Insulet this year.

    By • Dec. 7, 2023
  • Nick Jonas, Dexcom
    Image attribution tooltip
    Courtesy of Dexcom, Nick Jonas Super Bowl kit
    Image attribution tooltip

    Dexcom, Hologic picked to outperform in 2024: William Blair

    For the medtech industry overall, the analysts wrote that procedure volume growth is likely to normalize after declining due to the COVID-19 pandemic.

    By • Dec. 7, 2023
  • Boston Scientific's Farapulse pulsed field ablation device. Explore the Trendline➔
    Image attribution tooltip
    Permission granted by Boston Scientific
    Image attribution tooltip
    Trendline

    New medical devices are reshaping the medtech industry

    From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.

    By MedTech Dive staff
  • the FDA Headquarters
    Image attribution tooltip
    Sara Silbiger via Getty Images
    Image attribution tooltip

    Unomedical recall of infusion sets tagged as Class I by FDA

    The company notified Tandem Diabetes Care, its sole consignee, in October of the risk for infusion sets to detach from insulin pumps, disrupting insulin delivery.

    By • Nov. 28, 2023
  • Professional photo of Dev Kurdikar
    Image attribution tooltip
    Permission granted by Embecta
    Image attribution tooltip
    Q&A

    Embecta CEO Dev Kurdikar talks about growth expectations, GLP-1s

    The CEO said the company’s growth expectations have not changed in the near term, even with the rise of weight loss drugs.

    By • Nov. 21, 2023
  • People walk around a vertical screen that reads "Every 23 Seconds"
    Image attribution tooltip
    Permission granted by Abbott
    Image attribution tooltip
    Q&A

    Abbott Diabetes Care CMO Mahmood Kazemi on expanding CGM access

    Kazemi hopes anyone with diabetes will be able to access the technology, even people who don’t take insulin.

    By • Nov. 17, 2023
  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Wegovy study details revive debate over GLP-1 impact on devices

    The data confirmed a cardiovascular benefit for heart patients and showed the drug could help pre-diabetic patients control their blood sugar.

    By • Nov. 13, 2023
  • The Dexcom G7 Continuous Glucose Monitoring (CGM) System
    Image attribution tooltip
    Courtesy of Dexcom
    Image attribution tooltip

    NICE backs use of hybrid closed loop systems for Type 1 diabetes, if companies offer discounts

    The group’s recommendation gives around 150,000 people with Type 1 diabetes living in England the chance to access the systems, according to an NHS England official.

    By • Nov. 9, 2023
  • A smartphone on the left shows time in range, and a small, square device on the right is compared to a quarter in size.
    Image attribution tooltip
    Courtesy of Tandem
    Image attribution tooltip

    Diabetes tech firms focusing on Type 2 patients

    Leaders from Abbott, Dexcom, Tandem and Insulet expect Type 2 uptake of their insulin pumps and CGMs to accelerate as coverage improves and new devices reach the market.

    By • Nov. 7, 2023
  • A building in front of a pond with the sign "Medtronic" on a stone wall.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    5 companies to watch as medtech earnings wind down

    Zimmer Biomet, BD, Masimo, Illumina and Medtronic are all set to report financial results as the medtech earnings season draws to a close.

    By • Nov. 6, 2023
  • Boxes of the diabetes drug Ozempic are seen on a pharmacy counter.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    Drilling down on obesity drugs: What medtech executives are saying

    Investor concerns that interest in GLP-1s will slow demand for medical devices and procedures have shaved roughly $370 billion in value from stocks across the medtech sector, according to research by Mizuho.

    By • Nov. 2, 2023
  • An artificial intelligence processor unit
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GE HealthCare’s imaging AI will become ‘increasingly meaningful’ to growth: Moody’s

    Even if modestly accretive, AI could support longer-term revenue targets at GE HealthCare and its competitors, Moody’s analysts wrote.

    By • Oct. 27, 2023
  • A person looks at a black and white image on a screen as they hold an ultrasound device to another person's chest.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GE HealthCare, Novo Nordisk partner to use ultrasound to treat diabetes, obesity

    The collaborators will study the use of peripheral focused ultrasound as a non-invasive, non-pharmacological method of managing blood glucose.

    By • Oct. 25, 2023
  • A person sits in front of a plate of food, holding a smartphone. They're wearing a patch on their left arm.
    Image attribution tooltip
    Courtesy of Insulet Corp.
    Image attribution tooltip

    Insulet receives FDA clearance for Omnipod 5 iPhone app

    The application removes the need for patients with iPhones to carry a separate controller to manage bolus dosing.

    By • Oct. 23, 2023
  • Abbott FreeStyle Libre 3 sensor
    Image attribution tooltip
    Courtesy of Abbott
    Image attribution tooltip

    Abbott raises outlook amid strong Q3, sees momentum into 2024

    Sales of the FreeStyle Libre continuous glucose monitor rose nearly 31% despite investor worries about the potential impact of weight-loss drugs on demand.

    By • Oct. 18, 2023
  • Close-up of a sign with office building and trees in background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Boston Scientific wins diabetic neuropathy approval, joining rivals in growing market

    The expanded indication positions Boston Scientific to challenge Abbott, Medtronic and Nevro for the emerging opportunity in spinal cord stimulation to treat the condition.

    By • Oct. 12, 2023
  • A bright yellow sign against a blue roof says "Best Buy" in bold black letters.
    Image attribution tooltip
    Daphne Howland/MedTech Dive
    Image attribution tooltip

    Best Buy to sell continuous glucose monitoring systems

    It’s the tech retailer’s first foray into prescription-based medical device sales.

    By Rebecca Pifer Parduhn • Oct. 9, 2023
  • Professional photo of Wayde McMillan
    Image attribution tooltip
    Permission granted by Insulet
    Image attribution tooltip

    Insulet CFO leaves for 3M health spinoff

    Wayde McMillan is the second high-profile medtech executive in recent months to join 3M.

    By • Oct. 4, 2023
  • A grey reader shows a blood glucose reading, next to a white circular device
    Image attribution tooltip
    Permission granted by Abbott
    Image attribution tooltip

    Abbott data suggests GLP-1 drugs a ‘modest accelerator’ for CGMs: analysts

    The analysis of U.S. insurance claims found people on GLP-1 therapy wear their FreeStyle Libre sensors more.

    By • Sept. 29, 2023
  • A photo of a sign showing the Food and Drug Administration logo
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Intarcia’s diabetes drug-device combo voted down again by FDA panel

    The 19-member advisory committee unanimously voted against Intarcia in the review, citing cardiovascular and kidney safety concerns.

    By Gwendolyn Wu • Sept. 25, 2023
  • A white, rectangular sticker device is in front of a blue, pen-shaped device.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic receives CE mark for CGM sensor, boosting challenge to Abbott and Dexcom

    Medtronic has made the sensor smaller and eliminated the need for fingersticks to calibrate the device, bringing a challenger to market leaders Abbott and Dexcom. 

    By • Sept. 25, 2023
  • Professional photo of Jeffrey Brewer
    Image attribution tooltip
    Permission granted by Bigfoot Biomedical
    Image attribution tooltip
    Q&A

    Bigfoot CEO talks Abbott acquisition, future of diabetes tech

    Jeffrey Brewer hopes to see more integrated solutions for people with diabetes, starting with the company’s partnership with Abbott.

    By • Sept. 15, 2023
  • A person holds a rectangular device connected to tubing.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Insulin pump-makers grapple with questions about GLP-1s

    The new class of weight loss drugs has caused a stock selloff, but is unlikely to “meaningfully change the long-term outlook for diabetes,” analysts wrote.

    By • Sept. 14, 2023
  • Exterior of FDA headquarters
    Image attribution tooltip
    Courtesy of U.S. Food and Drug Administration
    Image attribution tooltip

    FDA proposes 3 guidances to improve 510(k) clearance process

    The agency has made recommendations for selecting predicate devices, using clinical data and conducting performance testing for implants.

    By • Sept. 7, 2023
  • White and black pen caps read "120 mg/dl" and a smartphone app says "Glucose in range."
    Image attribution tooltip
    Permission granted by Bigfoot Biomedical
    Image attribution tooltip

    Abbott to buy smart insulin pen cap maker Bigfoot

    The planned acquisition could shift patients interested in smart pens to Abbott’s Libre CGMs, an analyst wrote.

    By • Sept. 6, 2023
  • A phone app shows a chart with current glucose levels, next to a pen-shaped device.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic sued for allegedly sharing ‘treasure trove’ of diabetes patient data with Google

    The plaintiff said disclosures to Google are “particularly problematic” because his use of Gmail meant his personal information was “automatically linked to his real identity.”

    By • Sept. 5, 2023